Category Archives: Stem Cell Clinics


The Trouble With Stem Cell Therapy – Consumer Reports

Theres no shortage of opportunity for consumers like John Rodolf to encounter the promise and peril of experimental stem cell treatments. They are being studied by blue-chip medical centers like the Mayo Clinic, offered in the exam rooms of dermatologists and orthopedists, and advertised in newspapers and online by more than 500 stem cell specialty clinics.

The level of scientific vetting these treatments have been subjected to runs the gamut. Some have been carefully developed and sanctioned by the FDA; others havent been formally studied but have some evidence to support their use. Others still are untested and dangerously unscientific.

It can be difficult to tell which of those categories any given stem cell therapy falls into, in part because websites and advertisements that promote bogus treatments can look just as professional and trustworthy as the ones that discuss legitimate clinical trials. I found out about the Lung Institute in a magazine advertisement in my doctors office, says Maureen Rosen, a 75-year-old resident of Ocala, Fla., who, like John Rodolf, paid the Lung Institute thousands of dollars for COPD treatments she says didnt work at all. And it looked impressive to me. And when I went online, the website looked like any other website that youd see for a hospital.

Another problem is that questionable treatments are sometimes advertised alongside promising ones. For example, according to court documents and a case study published in the New England Journal of Medicine, three women suffered serious vision impairment (one went completely blind) after participating in a study they found listed at clinicaltrials.gov, a website maintained by the National Institutes of Health (NIH).

The site lists more than 1,000 stem cell-related clinical trials. Some of them have secured investigative new drug (IND) approval from the FDA, a process that can take years of research and involves careful vetting of protocols for safety and close monitoring of patients, as a rule. But other trials listed on the site havent completed those steps, and theres no easy way to tell the two groups apart.

The clinical trial that allegedly cost the three women their vision was administered at U.S. Stem Cell Clinic (USSCC) in Sunrise, Fla. It involved extracting stem cells from the womens belly fat and injecting them into their eyes to treat their macular degeneration. Researchers say the protocol violated basic safety principlessuch as treating only one eye so that the other would be spared in the event of complicationsand that it used a type of stem cell that hasnt demonstrated any potential for treating macular degeneration. Fat stem cells can only turn into fat, says Temple of the Neural Stem Cell Institute. Theres no reason to think they would do anything for diseases of the eye. U.S. Stem Cell Clinic declined to be interviewed for this article.

The NIH recently added a disclaimer to its clinical trials home page, warning that not all of the listed studies have been vetted by a federal agency. But critics say that notice isnt enough to protect consumers, many of whom are desperate for miracle cures. Some clinics effectively use this site as a marketing tool, says Leigh Turner, Ph.D., a bioethicist at the University of Minnesota who has studied the stem cell industry. They post studies there because it gives them an air of legitimacy, which in turn helps them attract patients.

An NIH spokeswoman told Consumer Reports that the government agency is considering additional measures to help consumers navigate the site better, but she didnt mention specifics.

Excerpt from:
The Trouble With Stem Cell Therapy - Consumer Reports

Orthobiologics Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By MRE – Cole of Duty

The Global Orthobiologies Market is expected to exceed more than US$ 10.0 Billion by 2025 at a CAGR of 7.5% in the given forecast period.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Anthrex, Zimmer Biomet, NuVasive, Inc., Orthofix, Inc., Wright Medical Technology, Globus Medical, Osiris Therapeutics, Inc., Genzyme, DePuy Synthes, Inc., Stryker Corporation, Smith & Nephew plc, Pioneer Surgical Technology, Bioventus LLC, Medtronic, Bone Biologics, Corp. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

You Can Browse Full Report: https://www.marketresearchengine.com/orthobiologics-market

Orthobiologics are the substances that are found in human beings in their body which is used for rapid curing process of wounds and injuries such as injured muscles, ligaments and broken bones. The use of orthobiologics are used in greater concentration, they help in accelerating curing action. The quick curing process, less number of hospital calls and visits, and increased healing are the advantages due to which orthobiologics are achieving importance in present scenario. Innovative technologies in biomaterials, used in the production of orthobiologics assume to increase the market demand. The sector is mainly driven by the growing number of orthopedic methods worldwide as an effect of an upturn in obesity and accidents. The fast increasing population globally, deeply vulnerable to spinal and other orthopedic disorders are also grant to the rising number of orthopedic procedures. These especially include corrections in graft designs, stem cell therapy, cultured tissue scaffolds and advent of recombinant biologic agents. The growth is backed with the benefits such as enlarged biocompatibility, lessened surgical time and smaller incisions. Moreover, these novel arrangements are dared to productively decrease the repeat of post-operative confusions, which consequently is relied upon to support the Orthobiologics market.

The Global Orthobiologies Market is segmented on the lines of its product, application, end-use and regional. Based on product segmentation it covers demineralized bone matrix (DBM), allograft and bone morphogenetic protein (BMP), viscosupplementation, synthetic bone substitutes and stem cell therapy. Based on application segmentation it covers spinal fusion, trauma repair, reconstructive surgery. Based on end-use segmentation it covers hospitals, orthopedic clinics. The Global Orthobiologies Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

The scope of the report includes a detailed study of global and regional markets on Global Orthobiologics Market with the reasons given for variations in the growth of the industry in certain regions.

The Global Orthobiologics Market has been segmented as below:

The Global Orthobiologics Market is Segmented on the lines of Product Analysis, Application Analysis, End-Use Analysis and Regional Analysis. By Product Analysis this market is segmented on the basis of Demineralized Bone Matrix(DBM), Allograft, Bone Morphogenetic Protein (BMP), Viscosupplementation, Synthetic Bone Substitutes and Stem Cell Therapy. By Application Analysis this market is segmented on the basis of Spinal Fusion, Trauma Repair and Reconstructive Surgery.

By End-Use Analysis this market is segmented on the basis of Hospitals sector and Orthopedic Clinics sector. By Regional Analysis this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World.

This report provides:

1) An overview of the global market for Global Orthobiologies Market and related technologies. 2) Analyses of global market trends, with data from 2015, estimates for 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2025. 3) Identifications of new market opportunities and targeted promotional plans for Global Orthobiologies Market. 4) Discussion of research and development, and the demand for new products and new applications. 5) Comprehensive company profiles of major players in the industry.

The major driving factors of Global Orthobiologies Market are as follows:

The restraining factors of Global Orthobiologies Market are as follows:

Request Sample Report: https://www.marketresearchengine.com/orthobiologics-market

Table of Contents

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Orthobiologics Market, By Product

7 Orthobiologics Market, By Application

8 Orthobiologics Market, By End User

9 Orthobiologics Market, By Region

10 Competitive Landscape

11 Company Profiles

11.1 Depuy Synthes (A Subsidiary of Johnson & Johnson)

11.2 Medtronic PLC.

11.3 Stryker Corporation

11.4 Zimmer Biomet Holdings, Inc.

11.5 Harvest Technologies Corporation (A Terumo Bct Company)

11.6 Globus Medical, Inc

11.7 Orthofix International N.V.

11.8 RTI Surgical, Inc

11.9 K2M Group Holdings, Inc

11.10 Kuros Biosciences Ltd.

11.11 Bioventus LLC

11.12 Nuvasive, Inc.

11.13 Seaspine Holdings Corporation

11.14 Arthrex, Inc

11.15 Xtant Medical Holdings, Inc

Other Related Market Research Reports:

Nitrogenous Fertilizers Market is Expected to Exceed US$ 127.00 Billion By 2022

Organ Preservation Solutions Market is Supposed to Reach US$ 300 Million By 2023

Phosphate Esters Market Size is Projected to be Around US$ 1,180.0 Million By 2022

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

See the original post here:
Orthobiologics Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By MRE - Cole of Duty

Trending: Canine Arthritis Therapeutics Market Research by Key players, Type and Application, Future Growth to 2026 – Cole of Duty

LOS ANGELES, United States: QY Research has recently published a report, titled Global Canine Arthritis Therapeutics Market Size, Status and Forecast 2020-2026.The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Canine Arthritis Therapeutics market. It informs readers about key trends and opportunities in the global Canine Arthritis Therapeutics market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Canine Arthritis Therapeutics market.

Key companies operating in the global Canine Arthritis Therapeutics market include , Elanco (Eli Lilly and Company), Boehringer Ingelheim, Zoetis Inc, Vetoquinol S.A., Bayer AG, Aratana Therapeutics Inc, Norbrook Laboratories Limited, VetStem Biopharma, Dechra Pharmaceuticals Plc Canine Arthritis Therapeutics

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/customize-request/form/1596595/global-canine-arthritis-therapeutics-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Canine Arthritis Therapeutics market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Canine Arthritis Therapeutics Market Segment By Type:

, Non-Steroidal Anti-Inflammatory Drugs, Opioids, Stem Cell Therapy Canine Arthritis Therapeutics

Global Canine Arthritis Therapeutics Market Segment By Application:

, Veterinary Hospitals and Clinics, Retail Pharmacies, Drug Stores

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Canine Arthritis Therapeutics market.

Key companies operating in the global Canine Arthritis Therapeutics market include , Elanco (Eli Lilly and Company), Boehringer Ingelheim, Zoetis Inc, Vetoquinol S.A., Bayer AG, Aratana Therapeutics Inc, Norbrook Laboratories Limited, VetStem Biopharma, Dechra Pharmaceuticals Plc Canine Arthritis Therapeutics

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1596595/global-canine-arthritis-therapeutics-market

TOC

1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Canine Arthritis Therapeutics Revenue 1.4 Market Analysis by Type 1.4.1 Global Canine Arthritis Therapeutics Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Non-Steroidal Anti-Inflammatory Drugs 1.4.3 Opioids 1.4.4 Stem Cell Therapy 1.5 Market by Application 1.5.1 Global Canine Arthritis Therapeutics Market Share by Application: 2020 VS 2026 1.5.2 Veterinary Hospitals and Clinics 1.5.3 Retail Pharmacies 1.5.4 Drug Stores 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions 2.1 Canine Arthritis Therapeutics Market Perspective (2015-2026) 2.2 Canine Arthritis Therapeutics Growth Trends by Regions 2.2.1 Canine Arthritis Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Canine Arthritis Therapeutics Historic Market Share by Regions (2015-2020) 2.2.3 Canine Arthritis Therapeutics Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porters Five Forces Analysis 2.3.5 Canine Arthritis Therapeutics Market Growth Strategy 2.3.6 Primary Interviews with Key Canine Arthritis Therapeutics Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Canine Arthritis Therapeutics Players by Market Size 3.1.1 Global Top Canine Arthritis Therapeutics Players by Revenue (2015-2020) 3.1.2 Global Canine Arthritis Therapeutics Revenue Market Share by Players (2015-2020) 3.1.3 Global Canine Arthritis Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Canine Arthritis Therapeutics Market Concentration Ratio 3.2.1 Global Canine Arthritis Therapeutics Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Canine Arthritis Therapeutics Revenue in 2019 3.3 Canine Arthritis Therapeutics Key Players Head office and Area Served 3.4 Key Players Canine Arthritis Therapeutics Product Solution and Service 3.5 Date of Enter into Canine Arthritis Therapeutics Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Canine Arthritis Therapeutics Historic Market Size by Type (2015-2020) 4.2 Global Canine Arthritis Therapeutics Forecasted Market Size by Type (2021-2026) 5 Canine Arthritis Therapeutics Breakdown Data by Application (2015-2026) 5.1 Global Canine Arthritis Therapeutics Market Size by Application (2015-2020) 5.2 Global Canine Arthritis Therapeutics Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Canine Arthritis Therapeutics Market Size (2015-2020) 6.2 Canine Arthritis Therapeutics Key Players in North America (2019-2020) 6.3 North America Canine Arthritis Therapeutics Market Size by Type (2015-2020) 6.4 North America Canine Arthritis Therapeutics Market Size by Application (2015-2020) 7 Europe 7.1 Europe Canine Arthritis Therapeutics Market Size (2015-2020) 7.2 Canine Arthritis Therapeutics Key Players in Europe (2019-2020) 7.3 Europe Canine Arthritis Therapeutics Market Size by Type (2015-2020) 7.4 Europe Canine Arthritis Therapeutics Market Size by Application (2015-2020) 8 China 8.1 China Canine Arthritis Therapeutics Market Size (2015-2020) 8.2 Canine Arthritis Therapeutics Key Players in China (2019-2020) 8.3 China Canine Arthritis Therapeutics Market Size by Type (2015-2020) 8.4 China Canine Arthritis Therapeutics Market Size by Application (2015-2020) 9 Japan 9.1 Japan Canine Arthritis Therapeutics Market Size (2015-2020) 9.2 Canine Arthritis Therapeutics Key Players in Japan (2019-2020) 9.3 Japan Canine Arthritis Therapeutics Market Size by Type (2015-2020) 9.4 Japan Canine Arthritis Therapeutics Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia Canine Arthritis Therapeutics Market Size (2015-2020) 10.2 Canine Arthritis Therapeutics Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia Canine Arthritis Therapeutics Market Size by Type (2015-2020) 10.4 Southeast Asia Canine Arthritis Therapeutics Market Size by Application (2015-2020) 11 India 11.1 India Canine Arthritis Therapeutics Market Size (2015-2020) 11.2 Canine Arthritis Therapeutics Key Players in India (2019-2020) 11.3 India Canine Arthritis Therapeutics Market Size by Type (2015-2020) 11.4 India Canine Arthritis Therapeutics Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America Canine Arthritis Therapeutics Market Size (2015-2020) 12.2 Canine Arthritis Therapeutics Key Players in Central & South America (2019-2020) 12.3 Central & South America Canine Arthritis Therapeutics Market Size by Type (2015-2020) 12.4 Central & South America Canine Arthritis Therapeutics Market Size by Application (2015-2020) 13 Key Players Profiles 13.1 Elanco (Eli Lilly and Company) 13.1.1 Elanco (Eli Lilly and Company) Company Details 13.1.2 Elanco (Eli Lilly and Company) Business Overview and Its Total Revenue 13.1.3 Elanco (Eli Lilly and Company) Canine Arthritis Therapeutics Introduction 13.1.4 Elanco (Eli Lilly and Company) Revenue in Canine Arthritis Therapeutics Business (2015-2020)) 13.1.5 Elanco (Eli Lilly and Company) Recent Development 13.2 Boehringer Ingelheim 13.2.1 Boehringer Ingelheim Company Details 13.2.2 Boehringer Ingelheim Business Overview and Its Total Revenue 13.2.3 Boehringer Ingelheim Canine Arthritis Therapeutics Introduction 13.2.4 Boehringer Ingelheim Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.2.5 Boehringer Ingelheim Recent Development 13.3 Zoetis Inc 13.3.1 Zoetis Inc Company Details 13.3.2 Zoetis Inc Business Overview and Its Total Revenue 13.3.3 Zoetis Inc Canine Arthritis Therapeutics Introduction 13.3.4 Zoetis Inc Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.3.5 Zoetis Inc Recent Development 13.4 Vetoquinol S.A. 13.4.1 Vetoquinol S.A. Company Details 13.4.2 Vetoquinol S.A. Business Overview and Its Total Revenue 13.4.3 Vetoquinol S.A. Canine Arthritis Therapeutics Introduction 13.4.4 Vetoquinol S.A. Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.4.5 Vetoquinol S.A. Recent Development 13.5 Bayer AG 13.5.1 Bayer AG Company Details 13.5.2 Bayer AG Business Overview and Its Total Revenue 13.5.3 Bayer AG Canine Arthritis Therapeutics Introduction 13.5.4 Bayer AG Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.5.5 Bayer AG Recent Development 13.6 Aratana Therapeutics Inc 13.6.1 Aratana Therapeutics Inc Company Details 13.6.2 Aratana Therapeutics Inc Business Overview and Its Total Revenue 13.6.3 Aratana Therapeutics Inc Canine Arthritis Therapeutics Introduction 13.6.4 Aratana Therapeutics Inc Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.6.5 Aratana Therapeutics Inc Recent Development 13.7 Norbrook Laboratories Limited 13.7.1 Norbrook Laboratories Limited Company Details 13.7.2 Norbrook Laboratories Limited Business Overview and Its Total Revenue 13.7.3 Norbrook Laboratories Limited Canine Arthritis Therapeutics Introduction 13.7.4 Norbrook Laboratories Limited Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.7.5 Norbrook Laboratories Limited Recent Development 13.8 VetStem Biopharma 13.8.1 VetStem Biopharma Company Details 13.8.2 VetStem Biopharma Business Overview and Its Total Revenue 13.8.3 VetStem Biopharma Canine Arthritis Therapeutics Introduction 13.8.4 VetStem Biopharma Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.8.5 VetStem Biopharma Recent Development 13.9 Dechra Pharmaceuticals Plc 13.9.1 Dechra Pharmaceuticals Plc Company Details 13.9.2 Dechra Pharmaceuticals Plc Business Overview and Its Total Revenue 13.9.3 Dechra Pharmaceuticals Plc Canine Arthritis Therapeutics Introduction 13.9.4 Dechra Pharmaceuticals Plc Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.9.5 Dechra Pharmaceuticals Plc Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Excerpt from:
Trending: Canine Arthritis Therapeutics Market Research by Key players, Type and Application, Future Growth to 2026 - Cole of Duty

Update on FDAs Comprehensive Regenerative Medicine Framework: Looming November 2020 Deadline Preceded by a Flurry of Letters from CBER and a New JAMA…

As we discussed in our last update on the Food and Drug Administrations Comprehensive Regenerative Medicine Policy Framework back in December 2019 (during the much simpler, pre-COVID-19 world), this coming November will conclude the three-year period of enforcement discretion announced by the agency when it first articulated the policies and goals of this comprehensive framework. In particular, under the dual-track program announced in 2017, the Food and Drug Administration (FDA) has been focused on: (1) clarifying the regulatory criteria for product marketing through guidance and providing support to legitimate product developers through formal and informal interactions; and (2) removing unapproved, unproven, and potentially unsafe products from the U.S. market.

None of the COVID-19-related operational updates provided by the FDA generally or by the Center for Biologics Evaluation and Research (CBER) in recent months has suggested that the November 2020 deadline will be extended or otherwise altered as a result of the ongoing public health emergency, even as certain other enforcement discretion policies have been put into place. Additionally, a recent editorial published by agency leadership and a noticeable increase in Warning/Untitled Letters to persons offering unapproved cellular therapy products, taken together, strongly suggest that folks in this industry that are currently operating outside of the applicable regulatory framework should not expect to be given any additional time to come into compliance.

June 2020 JAMA Editorial Strong Language and No Sign of a Deadline Extension

Multiple statements on the topic of regenerative medicine have been issued by the governing FDA Commissioner as well as CBER Director Peter Marks over the past several years, which indicates how important this area is to the agencys broader public health priorities at the start of the 21st century. The most recent salvo from agency leadership came in the form of an editorial published online by JAMA on June 17, 2020, authored by Dr. Marks and Commissioner Stephen Hahn, who has been in his new job for about six months. Their editorial includes some of the strongest language we have seen to date on the topic of unapproved regenerative medicine products. For example, Dr. Marks and Dr. Hahn state that [d]espite assertions by some individuals to the contrary, these products, whether autologous or allogeneic, are not inherently safe and may be associated with serious adverse consequences. They assert that [t]he increasing number of adverse events being reported following the widespread use of unapproved regenerative medicine therapies at hundreds of clinics across the country make it necessary for the FDA to act to prevent harm to individuals receiving them.

Drs. Marks and Hahn briefly highlight some of the enforcement that the agency has undertaken in this space since 2017 and ask for engagement from both clinicians and patients to help to ensure that instead of remaining unintentionally or intentionally hidden, potentially harmful unapproved regenerative medicine therapies are identified and removed from the market. They then provide basic guidelines for patients and caregivers to use when assessing whether a cellular therapy product is being offered in compliance with applicable laws and FDA regulations. Specifically, they recommend the following key considerations for anyone considering treatment with a cellular product:

Nothing in this newly-published editorial suggests that FDA/CBER will be taking its proverbial foot off the pedal to slow down its efforts towards further oversight of the private stem cell clinic industry after November 2020. To the contrary, the piece could represent one of the last informal warnings those businesses get from the agency before they receive a customized Warning or Untitled Letter or become subject to whatever increased enforcement activity the federal government initiates in this area in 2021 and beyond.

Relatively Large Number of Warning Letters Sent Since January 2020

We previously noted that FDA/CBER appeared to have increased the pace of issuing Warning and Untitled Letters to sellers of unapproved stem cell products during the second half of 2019, with many of those letters involving companies that processed and marketed unapproved umbilical cord blood-derived cellular products. We also reported that the agency had issued a Public Safety Notification on Exosome Products on December 6, 2019, informing the public of multiple reports of serious adverse events experienced by patients in Nebraska who were treated with unapproved products marketed as containing exosomes. That safety alert also described the unscrupulous conduct of sellers of such products in forceful and direct language, similar to the language used by Dr. Marks and Commissioner Hahn in this months editorial piece.

Over the first half of this year, as we get yet closer to the November 2020 deadline for stem cell clinics and medical practitioners to come into compliance with federal law, there has been a more noticeable increase in the Warning/Untitled Letters issues regarding the marketing of unapproved products that put patients at risk. These include at least nine Untitled Letters issued since January 2020 (which can each be accessed from this CBER webpage) and at least two Warning Letters, one from March and one from June. The Warning Letters in particular include charges that the firms in question were violating current good manufacturing practices (CGMPs) and current good tissue practices (CGTPs) for human cells and tissue products, putting patient safety at risk.

Interestingly, the most recent FDA Warning Letter issued on June 4, 2020 not only cites the recipient for marketing unapproved stem cell products and an unapproved exosome product, but it also states that the unapproved exosome product was being marketed for the treatment and prevention of COVID-19 something the June 17 Marks/Hahn JAMA editorial alluded to generally as well. Given that there are currently no FDA-approved products to prevent or treat COVID-19, any such claims will automatically heighten the enforcement risk to a company or physician engaged in the sale of products for those intended uses.

In addition to the work being done by FDA, moreover, the Federal Trade Commission (FTC) has also been monitoring the commercial marketplace closely and taking various actions to protect consumers from fraudulent COVID-19 products, including a few marketed by stem cell clinics. So far this month, FTC announced on June 4, 2020 that it had issued a 35 warning letters and an additional 30 warning letters on June 18, 2020. The first batch of these FTC warning letters notably included one to a stem cell clinic that, among other things, had claimed that stem cells can be administered intravenously and by inhalation through a nebulizer to treat lung damage caused by COVID-19 without scientific evidence to support the efficacy claim, while the second batch included two letters addressed to marketers of stem cell products.

FDA and the FTC coordinate quite closely on consumer protection matters that implicate both agencies primary missions, as is apparent from the large number of COVID-19 Warning Letters that have been jointly issued by the two agencies since March 2020. So they may very well be coordinating more actively now on the monitoring of stem cell clinics and individual physicians offering unapproved cellular therapies to the general public, as the focus shifts to the next phase of the Comprehensive Regenerative Medicine Policy Framework. The next five or six months should offer everyone more insight into what the enforcement landscape is likely to evolve into once the FDAs enforcement discretion period ends in November. As always, well keep our readers apprised of any notable developments.

[View source.]

Read the original post:
Update on FDAs Comprehensive Regenerative Medicine Framework: Looming November 2020 Deadline Preceded by a Flurry of Letters from CBER and a New JAMA...

Global Canine Stem Cell Therapy Market with (Covid-19) Impact Analysis: Future Development, Business Growth and Applications to 2025 – Cole of Duty

Researchstore.biz has released a new research report titled Global Canine Stem Cell Therapy Market 2020 by Company, Type and Application, Forecast to 2025 which offers a strategic evaluation of the market. The report presents prime parameters such as market size, revenue, sales analysis, and key drivers, and projection of the market by product, area, and use. The report delivers an in-depth analysis of the market with current and future trends. The report recognizes overall growth opportunities, industry drivers, obstacles, latest discoveries, and openings available for newcomers in the global Canine Stem Cell Therapy market.

Competitive Outlook:

The report further contains a competitive scenario of the major market players focusing on their sales revenue, customer demands, company profile, import/export scenario, business strategies that will help the emerging market segments in making major business decisions. In addition, their product portfolio, respective product applications, and product features have been emphasized in the report. The report also provides company shares and distribution shares data for the Canine Stem Cell Therapy market category and global corporate-level profiles of the key market participants.

DOWNLOAD FREE SAMPLE REPORT: https://www.researchstore.biz/sample-request/48453

NOTE: This report takes into account the current and future impacts of COVID-19 on this industry and offers you an in-dept analysis of Canine Stem Cell Therapy market.

The study profiles and examines leading companies and other prominent companies operating in the global Canine Stem Cell Therapy industry, covering: VETSTEM BIOPHARMA, VetMatrix, Aratana Therapeutics, Cell Therapy Sciences, Vetbiologics, Regeneus, ANIMAL CELL THERAPIES, Okyanos, Medivet Biologics, Magellan Stem Cells, Stemcellvet,

The far-reaching market study enlists a focused assessment of this business space and the regional landscape of this vertical. As per the report, the Canine Stem Cell Therapy market has established its presence across regions such as: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

On the basis of product, this report displays the production, revenue, price, market share, and growth rate of each type, primarily split into: Allogeneic Stem Cells, Autologous Stem cells

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share market growth rate for each application, including: Veterinary Hospitals, Veterinary Clinics, Veterinary Research Institutes

This search provides an analysis of indirect and direct sales channels, helps you to plan the right distribution strategy. The study also predicts the influence of different industry aspects on the global Canine Stem Cell Therapy market segments and regions. It delivers analysis on consumption volume, region-wise import/export analysis, and forecast Canine Stem Cell Therapy market from 2020-2025. At last, the report exhibits an analysis of leading marketing players, product specification, company profiles along with the contact details, production cost.

ACCESS FULL REPORT: https://www.researchstore.biz/report/global-canine-stem-cell-therapy-market-2020-48453

Important Aspects of Canine Stem Cell Therapy Market Report:

Customization of the Report: This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Researchstore.biz is a fully dedicated global market research agency providing thorough quantitative and qualitative analysis of extensive market research.Our corporate is identified by recognition and enthusiasm for what it offers, which unites its staff across the world.We are desired market researchers proving a reliable source of extensive market analysis on which readers can rely on. Our research team consist of some of the best market researchers, sector and analysis executives in the nation, because of which Researchstore.biz is considered as one of the most vigorous market research enterprises. Researchstore.biz finds perfect solutions according to the requirements of research with considerations of content and methods. Unique and out of the box technologies, techniques and solutions are implemented all through the research reports.

Contact Us Mark Stone Head of Business Development Phone: +1-201-465-4211 Email: [emailprotected] Web: http://www.researchstore.biz

The rest is here:
Global Canine Stem Cell Therapy Market with (Covid-19) Impact Analysis: Future Development, Business Growth and Applications to 2025 - Cole of Duty

Graham Company and Regenexx Announce Innovative Partnership to Reduce Orthopedic Surgical Spend for Employers – Stockhouse

PHILADELPHIA, June 23, 2020 /PRNewswire/ -- Graham Company, one of the country's largest insurance brokerages, today announced a new partnership with Regenexx, a network of leading interventional orthopedics clinics. The partnership gives Graham Company's self-insured clients the option to offer alternative non-surgical orthopedic treatment methods, provided by Regenexx through its expansive network of physicians, as a benefit enhancement for employees. In addition, the partnership will help Graham Company's clients control and reduce overall costs of orthopedic surgery procedures for employees.

According to data from Regenexx, its procedures have effectively intervened on 70% of elective orthopedic injuries and conditions where surgery was previously the only solution.* Regenexx offers a unique approach to treating orthopedic injuries non-surgically through stem cell therapy and other regenerative medicine. Procedures performed by Regenexx's specially trained physician network involve injections of custom orthobiologics, derived from the patient's own cells and natural healing agents, to treat approximately 40 orthopedic conditions. This interventional approach enables employers to save up to 70% of orthopedic costs by reducing the number of unnecessary surgeries performed annually.

"At Graham Company, we are committed to identifying solutions to help our clients control escalating health care costs while also enhancing their benefits offerings for employees," said Debra Montella, Graham Company's Vice President of the Employee Benefits Division. "Through this partnership with Regenexx, we are now able to present our self-insured clients with a unique approach that is transforming orthopedic care and driving down costs associated with surgical procedures."

This partnership also benefits the employees of clients with self-funded plans, providing them with alternative non-surgical treatment options to address orthopedic injuries or conditions. Regenexx company data found that when employees are given the choice between an invasive orthopedic surgery or its non-invasive procedure to treat orthopedic conditions, employees chose Regenexx's procedure a majority of the time. Compared to traditional orthopedic surgeries, Regenexx procedures require less downtime for patients and are considered less costly, less invasive and less risky.

"Regenexx is looking forward to expanding our mission of producing the best possible patient outcomes for Graham Company and their clients through our innovative alternative to orthopedic surgery," said Regenexx CEO Jason Hellickson. "Our patented regenerative approach to treating common orthopedic conditions is transforming the care pathway of an orthopedic patient who can now avoid a surgical encounter with less risk and less downtime."

*This data applies only to elective orthopedic surgery without fracture-related care and acute care trauma.

About Graham Company Graham Company is one of the largest insurance and employee benefits brokers in the country, committed to enhancing employee safety and business viability through an action-oriented approach to risk management. In business for nearly 60 years, Graham Company designs customized and effective property and casualty, surety and employee benefits programs for its clients to protect employees and prevent losses. With offices in Philadelphia, New York City and Washington, D.C., Graham Company became 100 percent employee-owned through an employee stock ownership plan in 2017. Through its innovative insurance and safety training programs, Graham Company is redefining what it means to be an insurance broker. To learn more, visit http://www.grahamco.com.

GRAHAM COMPANY IS AN INSURANCE BROKER AND NOT A MEDICAL CARE PROVIDER. ANY QUESTIONS CONCERNING THIS PROCEDURE SHOULD BE REFERRED TO REGENEXX OR YOUR MEDICAL CARE PROVIDER.

About Regenexx Regenexx is a nationwide network of physicians who practice Interventional Orthopedics, a new specialty that focuses on using the most advanced regenerative protocols available as an alternative to many orthopedic surgeries. Regenexx has published roughly half of the research worldwide on the use of orthobiologics for treating orthopedic injuries, and our patented treatment lab-processing and treatment protocols allow us to achieve unmatched results. Our procedures use your body's natural healing agents including blood platelets and bone marrow concentrate to repair damaged bone, muscle, cartilage, tendons and ligaments. We believe in educating patients, offering options and encouraging people to take an active role in their own treatment. For more information on Regenexx Corporate, visit http://www.regenexxcorporate.com or call 888-547-6667. For more information on the Regenexx procedures, visit http://www.regenexx.com.

View original content:http://www.prnewswire.com/news-releases/graham-company-and-regenexx-announce-innovative-partnership-to-reduce-orthopedic-surgical-spend-for-employers-301081460.html

SOURCE Regenexx

Originally posted here:
Graham Company and Regenexx Announce Innovative Partnership to Reduce Orthopedic Surgical Spend for Employers - Stockhouse

Stem Cell Cartilage Regeneration Market Overview By Growing Demands, Trends And Business Opportunities 2020 To 2027 – 3rd Watch News

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Stem Cell Cartilage Regeneration market.

Trusted Business Insights presents an updated and Latest Study on Stem Cell Cartilage Regeneration Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Stem Cell Cartilage Regeneration market during the forecast period (2019-2029). It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Global Stem Cell Cartilage Regeneration Market 2020 (Includes Business Impact of COVID-19)

Global Stem Cell Cartilage Regeneration Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2028 is a recent report generated by Trusted Business Insights. The global stem cell cartilage regeneration market report has been segmented on the basis of stem cell type, treatment, end user, and region.

Request Covid 19 Impact

Global Stem Cell Cartilage Regeneration Market: Overview

Stem cell-based therapy is important factor in functional replacement of cartilage regeneration. Stem cells are categorized into three kind of cells namely: hematopoietic stem cell, mesenchymal stem cells, and pluripotent stem cells.

Global Stem Cell Cartilage Regeneration Market: Dynamics

Rising adoption of minimally invasive surgery procedures, owing to its benefits such as lower risk and shorter duration for surgery is a key factor expected to drive growth of stem cell cartilage regeneration market over the forecast period.

In addition, increasing incidence of osteoarthritis among population across the globe, which in turn expected to support rising adoption of stem cell cartilage regeneration therapy. This factor is expected to boost growth of the target market over the forecast period.

Moreover, government initiatives such as government agencies which focusing on some policies in order to increase adoption of stem cell therapies is another factor expected to propel growth of target market over the forecast period.

However, higher treatment cost is a key factor expected to restrain growth of the global stem cell cartilage regeneration market over the forecast period. In addition, lack of skilled professionals to access stem cell sourcing, processing, or delivering these technologies is another factor expected to hamper growth of the target market over the forecast period.

Ongoing trend observed in the target market is increasing prevalence of osteoarthritis among population and rising adoption of minimally invasive surgery procedures which is turn expected to support growth of the global stem cell based cartilage regeneration market over the forecast period.

Increasing development of innovative technologies, products, and research and development (R&D) activities by key players are major factors expected to create potential revenue opportunities for the target market over the forecast period. In addition, increasing strategic partnership, merger, and acquisition activities by manufacturers are some other factors expected to create lucrative opportunities for player operating in the global market.

Global Stem Cell Cartilage Regeneration Market: Segment Analysis

Among the stem cell type segments, the mesenchymal stem cells segment is expected to register highest CAGR in the target market, owing to increasing research and development activities by various research organizations across the globe.

Global Stem Cell Cartilage Regeneration Market: Regional Analysis

The market in North America is expected to dominate in the global stem cell cartilage regeneration market in terms of revenue over the forecast period, owing to presence of key players operating in the target market such as Vericel Corporation, Osiris Therapeutics, among others and innovative stem cell based cartilage regeneration product launches, and development of new technologies across various countries in the region. In addition, rising geriatric population, which is more prone to degenerative disorders such as osteoarthritis across US is another factor expected to boost growth of the target market in this region.

The market in Asia Pacific is expected to register significant growth in terms of revenue over the forecast period, owing to stem cell based cartilage regeneration procedures are conducted by various hospital, specialty care, and clinics across India.

Global Stem Cell Cartilage Regeneration Market Segmentation:

Segmentation by stem cell type:

Hematopoietic Stem Cells (HSCs) Pluripotent Stem Cells (iPSC/ESCs) Mesenchymal Stem Cells (MSCs)

Segmentation by treatment:

Microfracture Osteochondral Transplant Autologous Chondrocyte Implantation Stem Cell Injections

Segmentation by end user:

Hospitals & Clinics Ambulatory Surgical Centers

Quick Read Table of Contents of this Report @ Global Stem Cell Cartilage Regeneration Market 2020 (Includes Business Impact of COVID-19)

Trusted Business Insights Shelly Arnold Media & Marketing Executive Email Me For Any Clarifications Connect on LinkedIn Click to follow Trusted Business Insights LinkedIn for Market Data and Updates. US: +1 646 568 9797 UK: +44 330 808 0580

More:
Stem Cell Cartilage Regeneration Market Overview By Growing Demands, Trends And Business Opportunities 2020 To 2027 - 3rd Watch News

Global Nerve Regeneration and Repair Market Growth Factors And Global Leading Players Are Abbott, Integra LifeSciences Corporation, Nevro Corp.,…

Global nerve regeneration and repair marketis registering a healthy CAGR of 12.95% in the forecast period of 2019-2026. This rise in the market value can be attributed to high incidences of nerve injuries globally. There are various technological advancement in the nerve repair technologies. There is a surge in the number of elderly population which is driving the market growth.

Few of the major market competitors currently working in the global nerve regeneration and repair market are Axogen Corporation, Boston Scientific Corporation, Alafair Biosciences, Medtronic, Baxter, Checkpoint Surgical., Abbott, Integra LifeSciences Corporation, Nevro Corp., Orthomed (UK) Ltd, Collagen Matrix, Inc., Cyberonics, Inc., Stryker, Polyganics, LivaNova PLC, Nuvectra, NeuroPace, Inc., Allen Medical Systems, Inc., Autonomic Technologies, Inc., COOK BIOTECH, INC., Elkem ASA, GlaxoSmithKline plc, Helius Medical Technologies, The Magstim Company Ltd., TissueGen among others.

Download Sample PDF Copy of Reporthttps://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-nerve-regeneration-and-repair-market

A class and transparency is strictly maintained while carrying out research studies of this nerve regeneration and repair market report to offer an exceptional market research report for a specific niche. By unearthing the best market opportunities, resourceful information is offered to prosper in the market. The report also measures market drivers, market restraints, challenges, opportunities and key developments in the market. With such data and facts it becomes easy to have an actionable ideas, enhanced decision-making and better mapping business strategies. Thus, the consistent and extensive market information of this report will definitely help grow business and improve return on investment (ROI).

Key Developments in the Market:

Table Of Content:

Part 01: Executive Summary Part 02: Scope Of The Report Part 03: Market Landscape

Part 04: Market Sizing

Part 05: Market Segmentation By Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape Part 08: Geographic Landscape

Part 09: Decision Framework Part 10: Drivers And Challenges

For More Insights Get Detailed TOC https://www.databridgemarketresearch.com/toc/?dbmr=global-nerve-regeneration-and-repair-market

Segmentation: Global Nerve Regeneration and RepairMarket

By Product

(Neurostimulation and Neuromodulation Devices, Biomaterials),

Indication

(Failed Back Surgery Syndrome, Parkinsons disease, Urinary Incontinence, Epilepsy, Gastroparesis, Nerve Repair, Grafting),

Application

(Neurostimulation and Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting, Stem Cell Therapy),

End User

(Hospitals and Clinics, Ambulatory Surgical Centers),

Geography

(North America, South America, Europe, Asia-Pacific, Middle East & Africa)

Inquire Regarding This Reporthttps://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-nerve-regeneration-and-repair-market

AboutData Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact: Data Bridge Market Research Tel: +1-888-387-2818 Email:[emailprotected]

Here is the original post:
Global Nerve Regeneration and Repair Market Growth Factors And Global Leading Players Are Abbott, Integra LifeSciences Corporation, Nevro Corp.,...

Canine Stem Cell Therapy Market to Expand with Significant CAGR – WorldsTrend

Health care stakeholders need to invest in value-based care, innovative care delivery models, advanced digital technologies. XploreMR will help you to know declarative, procedural, contextual, and somatic information about the Canine Stem Cell Therapy Market. It also provides a critical assessment of the performance of emerging and mature markets in a new publication titled Global Market Study on Canine Stem Cell Therapy: Ongoing Clinical Trials and Focus on Advancements to Push Adoption in Veterinary Clinics.

A synopsis of the global canine stem cell therapy market with reference to the global healthcare pharmaceutical industry

Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.

Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) and many more Information:https://www.xploremr.com/connectus/sample/2360

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.

Parent Indicators Healthcare

Research Methodology

XploreMR utilizes a triangulation methodology that is primarily based on experimental techniques such as patient-level data, to obtain precise market estimations and insights on Molecule and Drug Classes, API Formulations and preferred modes of administration. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.

Secondary research is used at the initial phase to identify the age specific disease epidemiology, diagnosis rate and treatment pattern, as per disease indications. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.

Primary research participants include demand-side users such as key opinion leaders, physicians, surgeons, nursing managers, clinical specialists who provide valuable insights on trends and clinical application of the drugs, key treatment patterns, adoption rate, and compliance rate.

Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project Year-on-Year growth rates. These Y-o-Y growth projections are checked and aligned as per industry/product lifecycle and further utilized to develop market numbers at a holistic level.

On the other hand, we also analyse various companies annual reports, investor presentations, SEC filings, 10k reports and press release operating in this market segment to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at Tier level based on their revenues, product portfolio and presence.

Please note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting will be done based on our internal proprietary model which also uses different macro-economic factors such as per capita healthcare expenditure, disposable income, industry based demand driving factors impacting the market and its forecast trends apart from disease related factors.

Get Full Access Of This Exclusive Report Right Now: https://www.xploremr.com/cart/2360/SL

Standard Report Structure

Target Audience

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type:

Application:

End User:

Region:

Continue reading here:
Canine Stem Cell Therapy Market to Expand with Significant CAGR - WorldsTrend

R3 International Now Offering New Stem Cell Therapy Program for Lyme Disease in Mexico – PR Web

Effective Stem Cell Program for Lyme disease (888) 988-0515

SAN DIEGO (PRWEB) June 08, 2020

R3 Stem Cell International announced that it is now offering a new program with stem cell therapy for Lyme disease. R3 has been offering effective treatment at its international clinics for a while, but with the new program patients receive more cost effective options with 100 to 200 million stem cells involved.

Stem cell treatment for Lyme disease in Mexico has been very effective at helping patients achieve symptom relief and regain an improved quality of life. Depending on a patient's history, the R3 International licensed provider will decide whether to add additional exosomes along with stem cells to the regimen.

The new program for Lyme disease involves either 150 million stem cells or 200 million. While these cell counts are incredibly high, it needs to be noted that the biologics come from a Mexico lab that achieves quality standards that exceed those of the FDA in the US.

There are two options for the Stem Cell Lyme disease program. One is a 5 day stay where Lyme patients receive several treatments during that time. The second option is for a patient to return to the Center for four visits over a year. The decision of which program to participate in is up to the patient and his/her family.

R3 Stem Cell International in Tijuana Mexico is only 20 minutes from the San Diego International Airport. R3 provides concierge escorted transportation to and from the clinic from San Diego, with hundreds of patients over the past year receiving successful care at the modern center.

The stem cell and exosome biologics used for Lyme disease care come from a lab that has an incredible safety record, and each treatment's biologic comes with a full Certificate of Analysis. Because Mexico allows stem cell culturing, the cell counts are extremely high with a viability of over 90%. No preservative is even necessary.

According to R3 International CEO David Greene, MD, MBA, "Patients and their families dealing with Lyme disease deserve a safe, clinically effective and cost effective option. We put that together in Mexico, with all inclusive treatment starting at $8975 which includes hotel and ground transportation. Tough conditions like Lyme disease necessitate large cell counts for optimal outcome, and most international centers charge 3 to 5 times our fees. Not with us!"

Each patient undergoes a free phone consultation with R3 International's licensed, experienced stem cell doctor. Simply call (888) 988-0515 to set one up.

Share article on social media or email:

Original post:
R3 International Now Offering New Stem Cell Therapy Program for Lyme Disease in Mexico - PR Web